Head and Neck Cancer
20-214-36/Nektar Propel-36
Official Title: A Phase 2/3, Randomized, Open-label Study to Compare Bempegaldesleukin Combined with Pembrolizumab Versus Pembrolizumab Alone in First-Line Treatment of Patients with Metastatic or Recurrent Head and Neck Squamous-Cell Carcinoma with PD-L1 Expressing Tumors (PROPEL-36)
Study Purpose: To compare the overall survival and the objective response rate of bempegaldesleukin plus pembrolizumab vs. pembrolizumab monotherapy.
Status:
Recruiting